AU2020288999A1 - Compositions and methods for treating central nervous system disorders - Google Patents

Compositions and methods for treating central nervous system disorders Download PDF

Info

Publication number
AU2020288999A1
AU2020288999A1 AU2020288999A AU2020288999A AU2020288999A1 AU 2020288999 A1 AU2020288999 A1 AU 2020288999A1 AU 2020288999 A AU2020288999 A AU 2020288999A AU 2020288999 A AU2020288999 A AU 2020288999A AU 2020288999 A1 AU2020288999 A1 AU 2020288999A1
Authority
AU
Australia
Prior art keywords
suramin
composition
less
patient
unit dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020288999A
Other languages
English (en)
Inventor
Michael Derby
Zachary ROME
Hock Seng Tan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PaxMedica Inc
Original Assignee
PaxMedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PaxMedica Inc filed Critical PaxMedica Inc
Publication of AU2020288999A1 publication Critical patent/AU2020288999A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020288999A 2019-06-07 2020-05-02 Compositions and methods for treating central nervous system disorders Abandoned AU2020288999A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962858621P 2019-06-07 2019-06-07
US62/858,621 2019-06-07
PCT/US2020/031217 WO2020247127A1 (en) 2019-06-07 2020-05-02 Compositions and methods for treating central nervous system disorders

Publications (1)

Publication Number Publication Date
AU2020288999A1 true AU2020288999A1 (en) 2022-02-03

Family

ID=73652889

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020288999A Abandoned AU2020288999A1 (en) 2019-06-07 2020-05-02 Compositions and methods for treating central nervous system disorders

Country Status (8)

Country Link
US (1) US20220226268A1 (enExample)
EP (1) EP3979985A4 (enExample)
JP (1) JP7749169B2 (enExample)
CN (1) CN114340597B (enExample)
AU (1) AU2020288999A1 (enExample)
CA (1) CA3142842A1 (enExample)
IL (1) IL288655A (enExample)
WO (1) WO2020247127A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116867487A (zh) * 2020-07-29 2023-10-10 完美日光有限公司 苏拉明的制造方法
US20230390226A1 (en) * 2020-10-22 2023-12-07 Paxmedica, Inc. Intranasal administration of suramin for treating nervous system disorders
IL302224A (en) * 2020-10-22 2023-06-01 Paxmedica Inc Administration of anti-purinergic preparations for the treatment of disorders of the nervous system
WO2023027994A1 (en) * 2021-08-23 2023-03-02 Paxmedica, Inc. Methods for treating nervous system disorders with antipurinergic agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002266A1 (en) * 1984-10-12 1986-04-24 United States Of America, Represented By The Unite Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav)
AU6527300A (en) * 1999-08-11 2001-03-05 Josef Pitha Potentiation of inclusion complex formation of cyclodextrin derivatives
US20050063940A1 (en) * 2002-02-25 2005-03-24 Sveinbjorn Gizurarson Bioadhesive agent
FR2867682B1 (fr) * 2004-03-22 2009-06-05 Galderma Res & Dev Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise.
EP1802287A2 (en) * 2004-09-27 2007-07-04 Sigmoid Biotechnologies Limited Minicapsule formulations
AU2007229866A1 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
FR2912591B1 (fr) * 2007-02-12 2009-05-01 Oberthur Card Syst Sa Procede et dispositif pour controler l'execution d'au moins une fonction dans un module de communication sans fil de courte portee d'un appareil mobile.
AR062239A1 (es) * 2007-08-07 2008-10-22 Civil De Estudios Superiores A Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal
US20120070487A1 (en) * 2010-03-24 2012-03-22 Aegis Therapeutics Llc Alkylsaccharide compositions with nutraceuticals
GB201401904D0 (en) * 2014-02-04 2014-03-19 Ziarco Pharma Ltd Pharmaceutical composition for topical administration
FR3025110B1 (fr) 2014-09-02 2016-12-23 Univ Francois-Rabelais De Tours Dispositif de pulverisation nasale de produit fluide
EP4541420A3 (en) * 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
JP7093559B2 (ja) * 2016-04-12 2022-06-30 トライジェミナ， インコーポレイテッド マグネシウム含有オキシトシン製剤および使用の方法
WO2018013811A1 (en) * 2016-07-14 2018-01-18 The Regents Of The University Of California Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders
WO2018148262A1 (en) * 2017-02-08 2018-08-16 Csp Pharma, Inc. Antipurinergic compounds and uses thereof
CN118697876A (zh) * 2017-02-09 2024-09-27 完美日光有限公司 用于自闭症谱系障碍药物治疗的方法
US11110060B2 (en) * 2017-10-25 2021-09-07 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents

Also Published As

Publication number Publication date
CA3142842A1 (en) 2020-12-10
JP7749169B2 (ja) 2025-10-06
JP2022535920A (ja) 2022-08-10
US20220226268A1 (en) 2022-07-21
CN114340597A (zh) 2022-04-12
WO2020247127A1 (en) 2020-12-10
EP3979985A1 (en) 2022-04-13
IL288655A (en) 2022-02-01
CN114340597B (zh) 2025-01-28
EP3979985A4 (en) 2023-05-03

Similar Documents

Publication Publication Date Title
JP7749169B2 (ja) 中枢神経系障害を処置するための組成物および方法
US20250241936A1 (en) Compositions and methods for treating an aggregation disease or disorder
JP2025087858A (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
KR20120092152A (ko) 타액선 기능장애의 치료
US20230390223A1 (en) Administration of antipurinergic compositions for treating nervous system disorders
US20230390226A1 (en) Intranasal administration of suramin for treating nervous system disorders
US12558367B2 (en) Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof
ES2729208T3 (es) Terapia basada en baclofeno y acamprosato de trastornos de degeneración macular
HK40073161B (zh) 用於治疗中枢神经系统障碍的组合物和方法
HK40073161A (en) Compositions and methods for treating central nervous system disorders
US20240277641A1 (en) Methods for treating nervous system disorders with antipurinergic agents

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted